Drug Safety Concerns Will Increase FDA-Industry Interactions, Schering Says
Schering-Plough predicts that increased attention on drug safety issues will drive greater interactions with FDA
You may also be interested in...
Jean-Louis Saillot was appointed Schering-Plough VP-Global Pharmacovigilance effective Jan. 20; he previously held the position on an interim basis. Saillot is responsible for global product safety surveillance, aggregate safety reporting, pharmacoepidemiology and clinical risk management. He will report to Schering-Plough Research Institute President Cecil Pickett...
FDA is understood to be developing a drug safety website as part of an initiative to address concerns about post-marketing surveillance
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011